Tetrahydrocannabivarin acid (THCVa) is the molecular precursor to Tetrahydrocannabivarin (THCV). Through decarboxylation, THCVa converts into THCV. The process of decarboxylation is when cannabis is exposed to sunlight or heat. THCVa is non-psychoactive so there is no high associated with this cannabinoid.
THCVa can be ingested raw and through juicing methods. THCVa does not seem to make any direct contact with CB1 or CB2 receptors. It is possible that tetrahydrocannabivarin acid works indirectly with CB1 receptors. This indirect binding underscores the potential therapeutic properties of this cannabinoid.
Though there has been limited research on Tetrahydrocannabivarin acid, THCVa’s possible benefits are identifiable. It is believed that it may act as a pain reliever and could reduce inflammation. Through other research, it is believed that THCVa contains anti-cancer properties, particularly when it comes to prostate cancer.
Tetrahydrocannabivarin is known for being an appetite suppressant. For that reason, individuals struggling with an eating disorder like anorexia should not use this cannabinoid. However, it may potentially help those battling obesity and overeating.
If an individual consumes high levels of raw tetrahydrocannabivarin acid, the cannabinoid will likely have the same effects as THCV—the non-acidic version of THCVa. THCV is known to help relieve symptoms of progressive diseases like Alzheimer’s. By association, it is assumed that THCVa holds the same potential.
Found in high levels within African sativa plants, this cannabinoid shows the potential to reduce panic and anxiety attacks in individuals that struggle with PTSD. This fact alone illustrates the importance it may hold for the millions of people suffering from this condition. Future research will teach us more about the benefits of THCVa.